Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-ranging study of evobrutinib in systemic lupus erythematosus
jRCT2080223900Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of evobrutinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Merck & Co. Started May 2018; status: completed.
02
Drugs
evobrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080223900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223900.